The c-MYC TF is an attractive target for cancer therapy because of the role that excessive c-MYC levels play in a broad spectrum of aggressive cancers (Felsher and Bishop, 1999; Jain et al., 2002; Soucek et al., 2008), but direct pharmacologic inhibition of c-MYC remains an elusive challenge in drug discovery (Bradner et al., 2017). Here, MYC is linked to cancer.